Moreover, most identified studies assessed therapeutic efficacy by measuring cerebral infarction size, whereas the impact of HDAC6 inhibition on neurological function was less widely reported and was assessed using varied tests which could not be easily compared. Here, HDAC6 is linked to cerebral infarction.